IP Library › Granted Patent US 10,098,867
Granted Patent B2
US 10,098,867 · App. 14/899,613 · Granted Oct 16, 2018

Use of phytocannabinoids in the treatment of ovarian carcinoma

Inventors: Farideh Afshin Javid (Huddersfield, GB); Marnie Duncan (Cambridge, GB); Colin Stott (Cambridge, GB)
Assignee: GW Research Limited
A61K31/352A61K31/05A61K31/192A61K31/353A61K36/185A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,098,867
App. No.
14/899,613
Granted
Oct 16, 2018
Kind
B2
Abstract

The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.

Claims (3)

1. A method for treatment of ovarian cancer comprising administering to a patient with ovarian cancer a combination of cannabidiol (CBD) and cannabigerol (CBG).

2. The method as claimed in claim 1 , wherein the CBD and CBG are in the form of an extract or botanical drug substance.

3. The method as claimed in claim 1 , wherein the CBD and CBG are in an isolated form.

Assignments (6)
CHANGE OF NAME Recorded Apr 24, 2026
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 074471/0255 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2019
From: OTSUKA PHARMACEUTICAL CO., LIMITED
To: GW PHARMA LIMITED
Reel/Frame 048619/0250 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER: 9685579 PREVIOUSLY RECORDED ON REEL 046609 FRAME 0822. ASSIGNOR(S) HEREBY CONFIRMS THE ASSET PURCHASE BY WAY OF DEED. Recorded Jan 30, 2019
From: GW PHARMA LIMITED
To: GW RESEARCH LIMITED
Reel/Frame 048187/0401 →
ASSET PURCHASE BY WAY OF DEED Recorded Jul 23, 2018
From: GW PHARMA LIMITED
To: GW RESEARCH LIMITED
Reel/Frame 046609/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2017
From: JAVID, FARIDEH AFSHIN; DUNCAN, MARNIE; STOTT, COLIN
To: GW PHARMA LIMITED
Reel/Frame 041748/0514 →
Priority Claims (2)
GB 1310910.3 · Jun 19, 2013 · national
GB 1406473.7 · Apr 10, 2014 · national
Continuity (1)
Related Publication 20160136128A1 · May 19, 2016
Cited By (25)
US 12,186,280 US 12,213,985 US 12,251,411 US 12,263,139 US 12,268,699 US 12,318,356 US 12,318,399 US 12,350,253 US 12,357,586 US 12,383,567 US 12,403,136 US 12,409,131 US 12,409,132 US 12,409,199 US 12,427,160 US 12,440,528 US 12,534,438 US 12,539,472 US 12,569,505 US 12,599,617 US 12,616,705 US 12,661,365 US 12,678,450 US 12,708,632 US 12,740,992